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ABSTRACT 
Tumor suppressor genes play a role as a growth regulator and a gatekeeper of a cell. Their 
inactivation is often detected in malignant tumors. Identification of novel tumor suppressor 
gene candidates may help to further understand tumorigenesis and aid in the discovery of  
a new treatment leading toward cure of cancer.  
This PhD research project aimed to understand functional significance of a novel tumor 
suppressor gene candidate, myosin IC (MYO1C) and to identify potential interaction(s) of the 
MYO1C protein with key components of the signaling pathways involving in cancer 
development. 
In an experimental rat model for endometrial carcinoma (EC), detailed molecular genetic 
analysis of a candidate tumor suppressor region located distal to the tumor protein 53 (Tp53) 
suggested the myosin IC gene (Myo1c) as the best potential target for deletion of the genetic 
material. The question arising was whether and how MYO1C could function as a tumor 
suppressor gene. By using qPCR, Western blot or immunohistochemistry analyses, we 
examined MYO1C protein level in panels of well-stratified human colorectal cancer (CRC) 
and EC respectively. We found that MYO1C was significantly down-regulated in these cancer 
materials and that for the EC panel, the observed down-regulation of MYO1C correlated with 
tumor stage, where tumors at more advanced stages had less expression of MYO1C. In cell 
transfection experiments, we found that over-expression of MYO1C significantly decreased 
cell proliferation, and silencing MYO1C with siRNA increased cell viability. Additionally, 
knockdown of MYO1C impaired the ability of cells to migrate, spread and adhere to the 
surface. Recent published studies suggested a potential interplay between MYO1C and the 
phosphoinositide 3-kinase (PI3K)/AKT pathway. To examine this hypothesis, we analyzed the 
expression and/or activation of components of the PI3K/AKT and RAS/ERK signaling 
pathways in vivo in CRC samples, and in vitro in cells transfected with the MYO1C gene 
expression construct or MYO1C-targeted siRNA. To identify other potential pathways/ 
mechanisms through which MYO1C may exert its tumor suppressor activity, we additionally 
performed new sets of MYO1C-siRNA knockdown experiments. At different time points post 
transfection, we performed microarray global gene expression experiments followed by 
bioinformatics analysis of the data. Altogether, the results suggested an early PI3K/AKT 
response to altered MYO1C expression. We additionally identified several cancer-related 
genes/pathways with late response to MYO1C knockdown. All things considered, the 
identification of MYO1C-expression impact on cell proliferation, migration, and adhesion in 
combination with its interplay between several cancer-related genes and signaling pathways 
provide further evidence for the initial hypothesis of a tumor suppressor activity of MYO1C.  
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SAMMANFATTNING 
Tumörsuppressorgener har en viktig roll i kontroll av celltillväxt och i att förhindra uppkomst 
av mutationer i arvsmassan. Inaktivering av dessa är ett viktigt steg i utveckling av maligna 
tumörer och därför kan identifiering av nya möjliga tumörsuppressorgener öka förståelsen för 
hur cancer uppstår och därmed ge ledtrådar till nya metoder för att bota cancer. 
Projektet i denna avhandling är fokuserat på att undersöka den funktionella relevansen av 
myosin IC (MYO1C), som potentiell tumörsuppressorgen, samt att identifiera vilka 
interaktioner MYO1C har med andra protein i signalvägar med betydelse i utveckling av 
cancer. 
Studier av en experimentell råttmodell av endometriecancer (EC) påvisade en genomisk region 
lokaliserad distalt om TP53 (p53) vilken kunde innehålla en eller flera möjliga 
tumörsuppressorgener. Detaljerade molekylärgenetiska studier av denna region indikerade att 
genen för myosin IC (Myo1c) skulle kunna vara en kandidatgen och mål för deletioner av 
genetiskt material i dessa modeller. Frågan är då om och hur Myo1c kan fungera som en 
tumörsuppressorgen? Genom kvantitativ PCR (qPCR) och immunohistokemi undersöktes 
uttrycksnivåerna av MYO1C i välstratifierade paneler av humana kolorektalcancer (CRC)- och 
EC-tumörer. Vi såg att uttrycket av MYO1C var nedreglerat i dessa cancergrupper och att 
iEC-tumörer så korrelerade proteinnivåerna med tumörstadium, där tumörer med mer 
avancerat stadium hade lägre nivåer av MYO1C. 
Genom cellbaserade försök visar vi att överuttryck av MYO1C signifikant minskar 
celltillväxten medan nedreglering av MYO1C med hjälp av siRNA ökar celltillväxten. 
Nedreglering av MYO1C leder också till försämrad kapacitet hos cellerna för migration och 
adhesion. Tidigare publicerade arbeten indikerar att det finns en koppling mellan MYO1C och 
phosphoinositide 3-kinase (PI3K)/Akt-signalering. För att undersöka denna hypotes 
analyserade vi uttryck och/eller aktivering av komponenter i PI3K/Akt eller MAPK 
signalering in vivo i kliniska CRC prover och in vitro i celler där MYO1C överuttryckts 
alternativt nedreglerats. För att identifiera andra möjliga mekanismer/signaleringsvägar genom 
vilka MYO1C kan utöva en tumörsupprimerande funktion undersökte vi genom microarray 
hur det globala genuttrycket förändrades över tid efter att MYO1C nedreglerats genom siRNA. 
Denna studie visade att nedreglering av MYO1C hade en tidig effekt på gener involverade i 
PI3K/Akt signalering.  
För att summera, effekten av ett modulerat MYO1C-uttryck på celltillväxt, migration och 
adhesion tillsammans med dess interaktion med andra cancerrelaterade gener och 
signaleringsvägar bidrar tillsammans att stärka den ursprungliga hypotesen att MYO1C har 
tumörsupprimerande funktioner. 
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1 INTRODUCTION 
1.1 Cancer 
Cancer is a group of genetic diseases characterized by uncontrolled cell 
growth and the invasion and spread of cells from the site of origin (primary 
site) to other sites of the body.  
Cancer can arise from all different cell types and tissues in the human body. 
The most common cancers in adults are the cancers that occur in epithelial 
cells and are called carcinomas while cancers of glandular tissues such as 
breast are called adenocarcinomas. Cancers derived from dividing cells in the 
pigment-containing cells known as melanocytes (and rarely in ocular retina), 
neurons and neural glia are called melanomas, retinoblastomas, 
neuroblastomas and glioblastomas respectively. Lymphomas and leukemias, 
sometimes referred to as the blood cell tumor or liquid tumors, develop from 
the tissues that give rise to lymphoid and blood cells. All of these diseases, 
from different cell types and in various locations are collectively group 
members of ‘cancer’. 
Environmental factors play a significant role in carcinogenesis and DNA is 
the critical target for environmental carcinogens, such as viruses, xenobiotic 
chemicals and radiation. It is believed that malignant transformation and 
tumor growth is a multi-stage process during which accumulation of several 
mutations that lead to deregulation of cell signaling pathways central to the 
control of cell growth and cell fate occurs [1]. Two major groups of genes 
responsible for cancer development are oncogenes and tumor suppressor 
genes. Tumor initiation and progression are results of the conversion of 
normal proto-oncogenes to activated oncogenes and/or inactivation of tumor 
suppressor genes.     
1.2 Genetic basis of cancer 
1.2.1 Tumor heterogeneity 
Cancer research has been trying to describe the precise mechanism that 
transforms normal cells in the human body into malignant tumor and to 
identify mutations in a subset of genes that enhance growth advantage [2].  
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The current studies show that the mutational profile and genomic landscape 
varies widely both within and between classes of cancer. Among all cancer 
cells, the subclones that pass through the selection pressure with the best 
evolutionary fitness will influence the cancer cell population, and each will 
be marked by the presence of mutations that provide a direct competitive 
advantage (driver mutations) and by others acquired during clonal evolution 
that contribute nothing to the subclone's oncogenic potential (passenger 
mutations) [2]. The alteration in these key drivers, once acquired by somatic 
mutation, triggers the development of cancer [3]. 
The significance of tumor heterogeneity is that tumors display substantial 
difference in terms of morphological and phenotypic profiles, including 
cellular morphology, gene expression profile, metabolism, motility, and 
angiogenic, proliferative, immunogenic, and metastatic potential. These 
distinctive events, occurring both between tumors (inter-tumor heterogeneity) 
and within tumors (intra-tumor heterogeneity), are to be stratified to the 
cancer subtypes in order to understand the development and design of cancer- 
and patient-specific treatment plans [4].  
1.2.2 Tumor suppressor genes 
Tumor suppressor genes are also called gatekeepers of the cell due to their 
role in controlling cell proliferation and their loss/deletion is often found 
during the development of tumors. According to Knudson’s “two-hit” model, 
for inactivation of a tumor suppressor gene, loss or inactivation of both 
alleles of the gene is required. For hereditary tumors, this model proposes 
that tumorigenesis requires a second somatic mutation while predisposed 
inherited germline mutation has already existed in the cells [5]. Inactivation 
of tumor suppressor genes can occur through deletion, mutation, epigenetic 
silencing, such as promoter methylation, or other mechanisms leading to a 
phenomenon called loss of heterozygosity as a consequence. Among different 
tumors, occurring of the repeated loss of heterozygosity in a given 
chromosome region suggests the presence of tumor suppressor gene in that 
region. There is a group of tumor suppressor genes identified as a 
haploinsufficient tumor suppressor. These genes are exceptions to Knudson’s 
“two-hit” model. In this small group of tumor suppressor genes, mutation of a 
single allele causes an increase in carcinogen susceptibility. 
1.3 Cell signaling pathway 
Over 45 years since the discovery of the first cancer-causing gene or 
‘oncogene’ to the coming forth of the new era for cancer treatment – those 
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targeted at specific signaling molecules, cancer research has been focusing on 
signal transduction related to the multistep development of human cancers. 
Those signaling pathways are invariably altered in cancer leading to an 
uncontrollable change in particular ‘Hallmarks of Cancer’ such as evading 
growth suppressors, sustaining proliferation, and resisting cell death [6].  
These interconnected pathways are being deciphered and depicted, but the 
most substantial challenge for all researchers across the world is set to 
understand the alterations that lead to cancer and how to correct them as 
defining the signaling mechanisms will define druggable targets and facilitate 
the development of effective therapies. 
Among the crucial pathways are those controlling cell growth, proliferation, 
and apoptosis, which coordinate a response to the cellular environment, with 
the phosphatidylinositol-3 kinase (PI3K) and the mammalian target of 
rapamycin (mTOR) as critical nodes. Both signaling pathways demonstrate 
the regulation of cell proliferation, survival as well as angiogenesis. Both 
non-malignant tumor cells and malignant tumor cells depend on these two 
pathways, which have an important role in the cellular response to hypoxia 
and energy depletion. Moreover, it is shown that aberrant activation of these 
pathways has been linked to the development of cancer [7]. 
1.3.1 Activation of PI3K /AKT signaling 
PI3K/AKT signaling is involved in diverse cell activities, including cell 
growth, survival, motility, and metabolism. Changes in this pathway are 
suggested as an essential step towards the initiation and maintenance of 
cancer development as somatic mutation and amplification of genes encoding 
key components of PI3K/AKT pathway has been reported in different cancer 
types [8, 9]. Therefore, there are several approaches to identify targets in this 
pathway for potential therapeutic approaches [10].  
Phosphatidylinositol 3 kinase (PI3K) is an intracellular lipid kinase enzyme 
that is involved in the addition of a phosphate to 3' hydroxyl group of the 
inositol at the hydrophilic head of the membrane-associated 
phosphatidylinositols and phosphoinositides. The family of the PI3Ks, was 
discovered in the 1980s. They are classified into three classes; class I (Ia and 
Ib), II, and III. The eight members of the PI3K family are classified into these 
three groups based on their primary sequence homology, domain structure, in 
vitro substrate preference, and mode of regulation [8, 11] and play a role as 
key regulators in various cell activities including cell growth, proliferation, 
differentiation, and survival [12]. With an exception of the p53 and 
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retinoblastoma (Rb) pathways, many components of this signaling pathway 
are affected by genomic alterations like mutation (germline mutation or 
somatic mutation), rearrangement, and amplification more often than any 
other pathways in human cancer [13] especially class Ia PI3K [14]. 
Research on PI3K signal transduction is mainly focused on PI3K class Ia.   
This class of PI3K enzymes includes heterodimers comprised of a p110 
catalytic subunit (with three isoforms: p110α, p110β, and p110δ) and a 
smaller p85 regulatory subunit (with five isoforms: p85α, p85β, p50α, p55γ, 
and p55α). The p85 regulatory subunit has two Src homology 2 (SH2) 
domain [15, 16]. The role for the p85 subunit is to maintain the p110 catalytic 
subunit in a low-activity state in inactive cells. Through direct interaction 
with activated growth factor receptor tyrosine kinases (RTK) or adaptor 
molecules like insulin receptor substrate 1 (IRS-1) at its SH2 domains, p85 
activates p110 [15-17].  
The PI3Ks transduce signals from various growth factors and regulators such 
as cytokines as major effectors downstream of receptor tyrosine kinases 
(RTKs) and G protein-coupled receptors (GPCRs). Transduction of the signal 
leads to generation of phospholipids that further activate serine/threonine 
protein kinase AKT, also known as protein kinase B (PKB), and its 
downstream components in the pathway [18]. The signaling pathway can also 
be activated by genetic hits that affect different components of the pathway 
[19]. 
Prior to signal transduction via PI3K, the inositols are in their inactive form 
as phosphatidylinositol-4,5-biphosphate (PtdIns(4,5)P2 or PIP2). Upon 
activation of PI3K, PIP2 becomes phosphorylated and PtdIns(3,4,5)P3 or PIP3 
is generated. PIP3 in turn targets those cytosolic proteins that have a 
pleckstrin homology (PH) domain, including the serine/threonine kinase 
AKT (protein kinase B, PKB). The interaction between PIP3 (in the 
membrane) and the PH domain of the AKT (at the vicinity of the membrane) 
causes this molecule to undergo structural conformational changes. These 
conformational changes result in exposure of two phosphorylation sites in 
AKT protein, threonine residue 308 (Thr-308) and serine residue 473  
(Ser-473) residues that subsequently become phosphorylated by PDK1  
(3-phosphoinositide-dependant kinase-1) and mTORC2 (mammalian target 
of rapamycin-rictor kinase complex) protein kinases, respectively and thus 
AKT becomes fully activated [16].  
Activated AKT in turn acts as a kinase enzyme that phosphorylates series of 
downstream signaling proteins, controlling three main biological effects 
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attributed to AKT activation: (1) facilitating cell survival by anti-apoptosis; 
(2) stimulating cell proliferation, and (3) promoting cell growth [16].  
On the other hand, dephosphorylation of PIP3 at D-3 or D-5 positions of 
inositol by enzyme phosphatase family members, e.g. PTEN (5’-phosphatase 
and tensin homolog) and/or INPP5K (inositol polyphosphate-5’-phosphatase 
K) leads to regulated termination of PI3K/AKT signaling [15-17, 20]. The 
haploinsufficient tumor suppressor PTEN is an important regulator to the 
PI3K/AKT signaling pathway. Inactivating mutations or deletion of PTEN 
results in constitutive activation of PI3K/AKT/mTOR axis [21]. 
The consequence of persistent activation of the PI3K signaling pathway leads 
to a disturbance of crucial cell activities as well as contributes to competitive 
growth advantage, metastatic competence, and resistance to treatment. 
Taking all the facts into account, the PI3K becomes an obvious target of 
choice for cancer treatment in contrast with other tumor-suppressor pathways 
such as p53 because amendment of activation by pharmacological 
intervention is easier than recovering the tumor-suppressor function [13]. 
1.3.2 The PI3K /AKT pathway as a target of 
treatment  
A variety of signals is integrated inside the cells to determine cell fate in term 
of survival and proliferation as well as to maintain the functions. It is rarely 
that a single checkpoint is for signaling convergence [22], but lots of research 
to date indicates that PI3K/AKT signaling axis is a gatekeeper for tumor 
growth. Being a central regulation point and therefore activated as a result of 
loss of function of tumor suppressor gene PTEN or gain of function 
mutations, this axis is a target of many attempts to develop therapeutic targets 
for a variety of cancers. 
Certain drug candidates, including pan-PI3K inhibitors, PI3K isoform 
specific inhibitors, and mTOR inhibitors, are being tested as monotherapy or 
as combinations in Phase II-III clinical trials in an array of cancer indications 
[19, 23]. Moreover, new candidates as dual PI3K/mTOR inhibitors (e.g. 
bay80-6946, GDC0980, BGT226 and PF-04691502) seem to be new 
development trend that is lined-up entering into Phase I clinical trials 
according to public data extracted from NIH Clinical Trials Registry 
(available at http://clinicaltrials.gov).    
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1.4 The MYO1C gene and protein  
The myosin IC (MYO1C) gene, also known as myosin I-beta (MMIb, MMIβ, 
MMI-beta), nuclear myosin I (NMI), and Myr2, is located adjacent to 
INPP5K on the human chromosome 17p13.3 (HSA17p13.3). This gene 
encodes a member of the unconventional myosin gene family, which is 
single-headed myosin molecule that dynamically links membrane to the actin 
cytoskeleton (Figure 1). There are three isoforms of the MYO1C protein, two 
of which are found in the cytoplasm and nucleus, whereas the third with a 
unique N-terminus containing additional 16 amino acids is found exclusively 
in the cell nucleus [24-26] (Figure 2).  
Figure 1. A schematic model of the full-length Myo1c protein (modified from Lu et 
al. [27]). Each Myo1c contains, a motor domain at N-terminus (blue), a regulatory 
domain (neck region; green) and a tail region (brown) at C-terminus. Illustration: 
Woranop Sukparangsi. 
From N-terminus to C-terminus, MYO1C contains a motor domain, a 
regulatory domain (neck region) consisting of several calmodulin (CaM)-
binding IQ motifs [28] and a tail region. The binding site at the regulatory 
domain appears to exert a non-specific binding, whereas the second binding 
site in the tail domain is more active in binding to membrane 
phosphoinositides. It has been shown that point mutations in the binding site 
at the tail domain of the protein inhibit the binding between MYO1C and 
PIP2 in vitro as well as disrupt binding to membrane and its cellular 
localization in vivo [29, 30]. This specific binding site has later been 
identified as an embedded pleckstrin homology (PH) domain, which allows 
MYO1C to tightly bind with soluble inositol phosphates e.g. InsP3 as well as 
PIP2 [31]. 
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Figure 2. Endogenous MYO1C is localized in both the nucleus and cytoplasm. 
Subcellular locations of MYO1C protein derived from COMPARTMENTS (available 
at http://compartments.jensenlab.org). Unified confidence scores of the localization 
evidence are assigned based on evidence type and source. Color-coded confidence 
scale is ranging from light green (1) for lowest confidence to dark green (5) for 
highest confidence. White (0) indicates an absence of localization evidence. 
There is no solid evidence suggesting a direct association of MYO1C to the 
PI3K/AKT pathway. However, there are some indications: during the glucose 
metabolism process, it has been shown that MYO1C is involved in insulin-
stimulated fusion of vesicles containing glucose transporter-4 (GLUT-4) with 
the plasma membrane by controlling the movement of these vesicles to the 
membrane [32]. Insulin-dependent phosphorylation of MYO1C through 
PI3K/AKT pathway was additionally shown to be mandatory for GLUT-4 
translocation [33]. In these studies, it was shown that enhanced 
polymerization of actin filaments by insulin stimulation through a PI3K-
independent mechanism could recruit MYO1C to the membrane through its 
actin-binding sites. This then resulted in the accumulation of GLUT-4-
containing vesicles at the cell cortex along with MYO1C-mediated 
membrane ruffling before they underwent fusion to the membrane. These 
events occurred in parallel with GLUT-4 translocation to the membrane for 
Cellular, Molecular and Functional Characterization of the Tumor Suppressor Candidate 
MYO1C 
8 
which PI3K activation was required. Thus, taken together, in response to 
insulin stimulation, activated MYO1C (through PI3K/AKT) is required for 
the mobilization of GLUT-4-containing vesicles to the cell membrane as well 
as for their anchoring to the actin cytoskeleton prior to fusion of vesicles to 
the membrane [32, 34]. In summary, through PI3K/AKT pathway, MYO1C 
is involved in glucose metabolism. 
There has been no previous report on potential tumor suppressor activity of 
MYO1C. However, there are reports on a cancer-related profile among other 
members of the myosin I gene family, such as MYO18B as a tumor 
suppressor gene identified in lung, ovarian and colorectal cancer [35-37] and 
MYO1F involved in gene fusion (chromosomal translocation) in infant acute 
monocytic leukemia [38].  
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2 AIM 
The ultimate goal of this PhD research project was to characterize functional 
significance of a recently identified tumor suppressor candidate, MYO1C, in 
tumorigenesis processes. In order to gain insight, various molecular and 
functional analyses using cell-based methods were carried out and classified 
clinical samples were analyzed. The specific aims of the studies included in 
this thesis were: 
Paper I: In this work, started before my PhD enrolment, we aimed to 
identify the most prominent tumor suppressor candidate(s) among a panel of 
19 genes located in a candidate tumor suppressor region distal to Tp53 using 
expression analysis in a panel of rat endometrial carcinoma compared to non-
malignant rat endometrium cells. Myo1c was one of the two identified targets 
in this region. 
Paper II: In this work, we aimed to investigate if MYO1C could influence 
expression and/or activation of a number of key components of the 
PI3K/AKT and RAS/ERK signaling pathways. Additionally, we aimed to 
examine functional significance of MYO1C over-expression or silencing on a 
number of cancer-related phenotypes e.g. cell proliferation, migration, and 
adhesion. Finally, we examined expression of MYO1C in a well-stratified 
panel of endometrial carcinoma to investigate for potential correlation 
between tumor stage/grade and MYO1C expression. 
Paper III: This work was set to investigate expression of the tumor 
suppressor candidate MYO1C in colorectal cancer clinical samples to assess 
potential correlation between MYO1C mRNA expression and protein level 
with the tumor stage. We further investigated the possible correlation 
between level of MYO1C and protein level and/or activation of a number of 
key components of the PI3K/AKT and RAS/ERK signaling pathways in the 
clinical samples. 
Paper IV: The potential interplay between MYO1C and the PI3K/AKT 
signaling pathway might not singularly explain cancer-related phenotypes 
exerted by MYO1C. Therefore, the present work was designed to explore 
other potentially involved genes and pathways in MYO1C exerted cancer-
related phenotypes. The goal was to identify a number of novel genes and 
pathways expression of which was significantly altered in response to 
MYO1C knockdown, suggesting an interplay between these genes/pathways 
and MYO1C. 
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3 MATERIALS AND METHODS 
The present PhD research project used both clinical samples and genetic 
materials derived from cell culture to investigate alterations in the central 
dogma of biology at different levels from DNA to translated protein by 
performing various molecular techniques (Figure 3).
Figure 3. Schematic summary of different methods and assays performed in the
present PhD research project. A crystal structure of protein reproduced and modified 
courtesy of the RCSB Protein Data Bank [39] 
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3.1 Clinical samples and cell lines  
Human tumor samples 
In Paper II, a total of 62 human endometrial carcinomas (EC) were analyzed. 
The tumor samples were randomly selected based on their pathology in the 
tissue bank of paraffin blocks at Sahlgrenska University Hospital and 
classified according to FIGO staging for endometrial carcinoma (Table 1). 
Table 1. EC tumor samples used in Paper II and their stages according to 
FIGO staging for carcinoma of the endometrium [40, 41]. 
Stage (Description) Number of samples 
  Hyperplasia 10 
  Stage I (highly differentiated) 19 
  Stage II (intermediately differentiated) 24 
  Stage III (poor differentiated) 19 
Total 62 
In Paper III, we used a panel of 24 surgically removed CRC samples, 12 from 
colon and 12 from rectum, obtained from Sahlgrenska University Hospital, 
paired with their corresponding normal-appearing colon or rectum mucosa 
located 10 cm away from the location of the tumor from each patient. All 
specimens were pathologically staged according to Duke’s classification  
[42, 43] (Table 2). Total RNA was extracted from tissue samples using 
RNAeasy mini kit (Qiagen) according to manufacturer’s protocol and protein 
extraction was made from frozen homogenized tissue samples with RIPA 
lysis buffer (Thermo Scientific).   
Table 2. CRC tumor samples and stages according to Duke’s classification 
used in Paper III. 
Stage Colon cancer Rectal cancer Total 
  Stage II 5 3 8 
  Stage III 5 6 11 
  Stage IV 2 3 5 
Total 12 12 24 
All experiments on human tumor samples were approved by the local ethical 
committee (Sahlgrenska Academy, University of Gothenburg). 
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Experimental tumor materials, cell lines and culture  
In Paper I, ECs developed in animals of inbred rat strain BDII/Han were used 
as the experimental model for EC. The virgin females of this rat strain 
spontaneously develop endometrial cancer at a high frequency (more than 
90%) before the age of 24 months [44, 45]. To obtain the tumor material used 
in this study, rats from the BDII strain were crossed with rats from the two 
inbred rat strains BN and SPRD that have a very low frequency of EC, and a 
F1 progeny was developed. A backcross was performed by mating 
heterozygote males (BDII/BN or BDII/SPRD) with female BDII rats and in 
this backcross about 25 percent of the progeny developed EC [46] (Figure 4). 
After the pathological assessment, in some cases, no malignant cells could be 
detected. In cytogenetic analysis, these samples showed only minor 
numerical chromosomal aberrations; these samples were referred as non-
malignant endometrium (NME) and used as control samples. At necropsy, 
the tumor specimens were collected for DNA extraction with Genepure 341 
Nucleic Acid Purification System (PE Applied Biosystems). Small pieces of 
fresh tumor as well as NME were transferred to set up primary cell cultures. 
Later on, DNA and total RNA were extracted from the cultures using 
GenElute kit (Mammalian Total RNA Kit, Sigma).  
Figure 3. Crossing schedule for the BDII rats. The N1 (backcross) progeny is used 
in this study. 
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All animal works were performed under supervision of Professor Hans J. 
Hedrich and approved by the local ethical committee (Institute of Laboratory 
Animal Science and Central Animal Facility, Hannover Medical School, 
Germany). All cell lines used in Paper I were established from fresh tissues at 
CMB-Genetics, University of Gothenburg, Gothenburg, Sweden. 
In Paper II, HEK-293 (or 293) cells (human embryonic kidney cell line, 
American Type Culture Collection, ATCC) and HeLa cells (Sigma-
Aldrich/The European Collection of Cell Cultures, ECACC) with limited  
de novo protein expression of MYO1C were used for MYO1C gene 
expression transfection studies.  The cell lines were cultured in DMEM 
medium, supplemented with 10% bovine growth serum (BGS), 1% penicillin 
and streptomycin (PEST).  
In paper II and IV and for siRNA gene silencing experiments the 
immortalized normal breast epithelium MCF10A cells (Michigan Cancer 
Foundation, ATCC) with medium to high de novo protein expression of 
MYO1C were used. The cells were cultured, as described earlier [47], in 
DMEM/F12 medium, supplemented with 5% horse serum, 20 ng/ml 
epidermal growth factor (EGF), 0.5 mg/ml hydrocortisone, 100 ng/ml cholera 
toxin, 10 µg/ml insulin, 1%  PEST.  
All cells were cultured in the atmosphere of 5% carbon dioxide at 37°C.  
3.2 Analyses at DNA level 
DNA sequencing for mutation analysis 
DNA sequencing is a method to determine precise order of nucleotides within 
a DNA molecule. It is a classic method to identify mutation in DNA 
sequence or change in nucleic acid by different mechanisms e.g. substitution, 
insertion or deletion. The change in DNA sequence that alters protein-coding 
sequence is called frameshift mutation. The original sequencing method was 
firstly introduced by Sanger et al. in 1977 [48] after a report of DNA 
polymerase usage for primed synthesis in 1975 [49]. The sequencing 
technique makes use of the 2',3'- dideoxynucleotide (ddNTP) analogs. Once 
the ddNTP is incorporated, it results in chain termination as ddNTPs lacks 
the hydroxyl group at 3' carbon atom that allows chain elongation.         
In Paper I, based on the availability of material and the genetic background,  
a panel of 32 EC was selected for mutation sequencing of Myo1c. Primer 
pairs were designed by a commercial supplier, SIGMA-Genosystem. PCR 
primers set corresponding to the coding sequence were amplified and 
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screened for mutations. We also sequenced the promoter region of Myo1c. 
Sequencing products were separated on a denaturing polyacrylamide gel on a 
3130xl Genetic Analyzer (Applied Biosystems) and analyzed using the 
software’s Sequencing Analysis v5.2 and SeqScape v2.5 (Applied 
Biosystems). DNA sequencing was also performed to verify the sequence of 
a full-length insert of MYO1C in a construct for down-stream overexpression 
experiment (Paper II).     
DNA methylation and analysis  
Hypermethylation of a gene promoter is an important process to negatively 
regulate gene transcription and inactivation of a gene. In paper I, promoter 
methylation analysis was performed using a panel of DNA samples, 14 
experimental ECs and three NMEs (control). The DNA samples were 
subjected to bisulfite modification and purified using Epitech Bisulfite Kit 
(Qiagen) according to the protocol from manufacturer. In theory, treatment 
with bisulfite causes deamination and turn unmethylated cytosines to uracils. 
During the amplification by PCR, the deaminated cytosines that converted to 
uracils are recognized as thymines in the sequencing analysis. In this 
experiment, we used web server CpG Island Searcher (URL: 
http://www.uscnorris.com/cpgislands2/cpg.aspx) to predict the location of 
CpG islands that associated with the promoter regions. Primers suitable for 
bisulfite sequencing were designed using the MethPrimer software (URL: 
http://urogene.org/methprimer/) and BiSearch web server (URL: 
http://bisearch.enzim.hu/) and synthesized by a commercial supplier 
(SIGMA-Genosystem). Promoter regions were amplified using three 
different overlapping sets of primers for Myo1c using treated DNA as a 
template. The methylation status was then analyzed using bisulfite 
sequencing as described in Carén et al. [50]. 
DNA demethylation and restoration of gene expression  
In Paper I, four experimental EC cell lines, NUT12 and NUT50 with- and 
NUT51 and NUT98 without deletion/AI (allelic imbalance) at the candidate 
tumor suppressor region and all with low expression of Myo1c, as well as rat 
embryo fibroblasts (REF) as control, were selected for the analysis. All cell 
cultures were treated with the demethylating agent 5-aza-2 ́-deoxycytidine (5-
Aza-dC, Sigma-Aldrich) and/or with the histone deacetylase inhibitor 
trichostatin A (TSA; Sigma-Aldrich). Total RNA was isolated from using 
RNeasy Protect Mini kit (Qiagen) according to the manufacturer’s protocol. 
Protein extraction was performed according to standard protocol. This 
analysis assisted us to understand if epigenetic regulation was the rationale of 
low expression of Myo1c in tumor samples tested.   
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3.3 Analyses at RNA level 
Polymerase chain reaction (PCR) and  
reverse transcription PCR (RT-PCR) 
The polymerase chain reaction (PCR) is an in vitro molecular technique to 
amplify small amounts of DNA fragments of interest in an exponential 
pattern. For each cycle, the DNA made in the previous cycles also serves as 
template. This technique was invented in the 1980s and later patented by 
Kary Mullis [51, 52]. The method relies on thermal cycling, consisting of 
cycles of repeated heating and cooling of the reaction for DNA denaturation, 
hybridization, and enzymatic replication (Figure 5). These steps are usually 
repeated 20-35 rounds before depletion of the starting components occurs. 
Primers containing specific sequences complementary to the target region 
along with a thermostable DNA polymerase, which the method is named 
after, are key features to enable amplification using PCR technique [53, 54].  
Figure 4. Step in PCR amplification of DNA consisting of 3 steps; denaturation, 
annealing, and elongation.  
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The products of PCR are usually examined by running on 0.5-2% agarose gel 
electrophoresis after staining with fluorescent dye such as ethidium bromide 
or non-toxic Gel Red (Biotium) to enable observation under ultraviolet light. 
By observation, it allows size estimation of PCR product run in parallel with 
the DNA ladder and amount estimation by measuring the band intensity. This 
method was used in Paper II to verify the genomic insert in a DNA construct 
for MYO1C during the cloning process. In addition, a modified variant of the 
PCR technique for the analysis of gene expression at RNA level (reverse 
transcription PCR or RT-PCR) was used in Paper I and IV to observe gene 
expression. In RT-PCR, the starting material is a complementary DNA 
(cDNA) that is produced from RNA through a reverse transcription process. 
Real-time reverse transcription PCR (real-time RT-PCR) 
Real-time RT-PCR, also known as quantitative PCR (qPCR), is a variant of 
PCR, in which amplification and detection (quantification) of cDNA is 
performed at the same time. This method allows real time quantification of 
the starting material based on signals from non-specific fluorescent DNA-
binding dyes or sequence-specific DNA probes labeled with a fluorescent 
reporter during each cycle of PCR. This method was performed for 
quantitative examination of the gene expression in Paper I. A set of 
housekeeping genes, including Gapdh, Actb, and Rps9, was used for 
normalization. The quality control and data analysis were performed 
according to the Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) guidelines [55].    
Microarray analysis 
          
Figure 5. 3D-microarray chip filled with 
white beads in the black resin slide. 
Courtesy of Toray Industries.  
DNA microarray analysis is a 
technique used to determine gene 
expression from the starting 
material mRNA. In Paper IV, we 
used a 3D-microarray system (3D-
Gene, Toray Industries) that is a 
black colored chip (Figure 6) to 
analyze potential time-dependent 
alterations in expression of all of 
the 25000 annotated and predicted 
genes in response to MYO1C 
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depletion. The 3D-microarray system is a variant of the conventional 2D-
microarray technique with special features that allow effective elimination of 
the background noise and more specific binding of target sequences to the 
probes. These features include 1) use of black resin substrate with dye 
absorbing autologous fluorescence to reduce the background noise; 2) the 
DNA probe is immobilized on a special unique surface to enable dense and 
uniform immobilization of probe; 3) the surface that probes are immobilized 
to are located at the upper end of an uneven columnar structure to enable the 
stabilization of spot morphology and a uniform signal detection; 4) and 
constantly active bead agitation enhancing DNA hybridization, thus increases 
signal intensity.  
Clustering and identification of regulatory events 
In Paper IV a data set from 3D-microarray analyses was produced and 
subjected to bioinformatics analysis. The microarray data was clustered using 
the Short Time-series Expression Miner (STEM) [56] v1.3.8 according to 
their expression pattern across all time points. For this analysis, standard 
settings were used except that the minimum absolute expression change was 
measured between the maximum and minimum (rather than the difference 
from t = 0) and that the option “No normalization/add 0” was chosen. To 
normalize for differences in absolute expression values, the gene expression 
vectors used in this analysis contained the ratio of expression between 
MYO1C-siRNA treated and scrambled-siRNA treated for each of the time 
points.  
The Dynamic Regulatory Events Miner (DREM) [57] v2.0 was used to 
derive a regulatory map indicating bifurcation events and identifying 
candidate transcription factors causing the major changes in the expression. 
Standard settings were used except that expression differences were 
measured between the maximum and minimum, and that path merges were 
allowed. The maximum number of paths out of a split was set to four. 
Annotation and pathway analysis 
Annotation enrichment analysis was performed in Paper IV using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
[58]. Pathways discovered by clustering and found in the KEGG database 
(Kyoto Encyclopedia of Genes and Genomes) were analyzed for enrichment 
using the desktop version of the Gene Set Expression Analysis (GSEA) 
software v2.1.0 [59].  
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3.4 Analyses at protein level 
Western blotting 
The Western blot or immunoblot is a semi-quantitative method to detect 
specific protein using the interaction between an antibody and target antigen 
that is usually a protein or peptide. This technique was firstly introduced by 
Towbin et al. in 1979 [60, 61]. The specificity of the interaction is 
determined by an epitope (small fragment of the antigen) and recognition 
sites on the molecule of an antibody. To increase the specificity, two types of 
antibodies are used; a primary antibody that is specific to the protein of 
interest and a secondary antibody that is a counterpart to the primary 
antibody which now serves as an ‘antigen’. This method was used in Paper  
I, II and III to examine the protein expression.   
The detection is achieved by using a conjugated secondary antibody. In this 
PhD research work, the chemiluminescent system, in which peroxidase 
enzyme tagged to secondary antibody cleaves the substrate allowing light 
emission to be detected was used. The signals were recorded with a LAS1000 
camera (Luminescent Image Analyzer, LAS1000 Plus, Fuji-Film, Japan) 
using Image Reader LAS1000 V2.6 program. Western blots were performed 
at least independent triplicates for each protein extraction experiment. 
Immunoblotting signals were quantified by ImageJ (http://rsbweb.nih.gov/ij) 
and protein levels were calculated and presented as relative protein level after 
normalized against the protein expression of GAPDH. 
Immunohistochemistry analysis  
Immunohistochemistry (IHC) is a technique to detect the protein of interest 
in situ using an antibody against the target protein in cells of a tissue section 
by exploiting the principle of immunological specificity, binding between 
antibodies and antigens in biological samples. The assay was firstly 
implemented by Albert Coons in 1941 [62]. IHC is widely used in clinical 
research to determine distribution and localization of differentially expressed 
protein of interest and cellular biomarkers within cells and in the tissue 
section. Visualization is achieved by using secondary antibodies conjugated 
with an enzyme, e.g. horseradish peroxidase (HRP) or alkaline phosphatase 
(AP), which can produce either chromogenic insoluble precipitates or 
fluorescent signals. 
In paper II, this method was used to evaluate MYO1C protein expression in  
a panel of 62 paraffin-embedded EC samples. The signals were evaluated 
using conventional light microscopy, following parameters were recorded: i) 
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localization of the signal in cells with positive staining, ii) the intensity of the 
signal (0 to 4) in the tumor cell population, and iii) fraction of positive cells 
in the tumor cell population. Corresponding sections stained with 
haematoxylin-eosin were used to determine areas of tumor in each section. 
3.5 Cell-based functional assays 
Cell transfections 
The transient transfections used in the present PhD research work was  
a liposome-mediated transfection technique, in which liposomes were used to 
deliver either DNA construct or siRNA into the target mammalian cells [63]. 
In Paper II and IV, we performed transfection to manipulate gene expression 
either to over-express or knockdown the target gene, MYO1C, using gene 
expression construct carrying full-length MYO1C or siRNA targeting 
MYO1C, respectively.  
The vectors or plasmid used in gene overexpression transfection experiments 
are autonomously replicating DNA molecules that are used to carry foreign 
DNA fragments into the transfected cells [64]. The vector is constructed to 
contain regulatory sequences that act as enhancer and promoter regions and 
lead to efficient transcription of the gene inserted in the expression vector.  
It also contains antibiotic-resistance genes to facilitate identification of the 
positive clones (clones with correct insert and correct orientation) during the 
screening process. Use of expression vector for overexpression experiments 
is a basic tool for understanding the effect of gene expression and its 
translated products in mammalian cells [65]. 
The siRNA (short interfering RNA or silencing RNA) is a synthetic RNA 
duplex of 20-25 base pairs length that specifically targets a mRNA molecule. 
The effect of siRNA in RNA interference (RNAi) depends on its 
complementary binding to the target mRNA; it can lead to either inhibiting 
translation or directly causing degradation of the transcript. The first report of 
siRNA utilization in mammalian cells was introduced in the early 2000s by 
Thomas Tuschl et al. by the name of the RNA interference process [66]. 
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Cell proliferation assay 
The assay was performed in Paper II to examine cell proliferation, which is 
the cellular process to increase the number of viable cells in balance or 
compensation with the cell loss through cell death or differentiation.  
The assay used in this work is based on the use of tetrazolium compound [3-
(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron-coupling reagent (phenazine 
ethosulfate; PES) [67, 68]. In brief, the viable cells metabolize the 
tetrazolium compound in to an insoluble colored product, formazan. The 
quantity of metabolized formazan, directly proportional to the number of 
living cells in culture, is measured at 490 nm-absorbance and recorded using 
Mithras LB940 (Berthold Technologies) with the program MikroWin v.4.31 
(Mikrotek Laborsystems). 
Cell migration assay 
Cell migration is a basic cellular process in the development and maintenance 
of multicellular organisms. Tissue formation during embryonic development, 
wound healing and immune responses all require the orchestrated movement 
of cells in particular directions and to specific locations.  
In cancer, this process may imply to invasion to adjacent tissue, penetration 
into vascular system or metastasis to distant location of the body. In paper II, 
we performed migration assay using OrisTM Cell Migration Assay plates 
(Platypus Technologies), containing a cell-seeding stopper. First, cells were 
allowed to attach and spread overnight at 37°C before the stoppers were 
removed and the medium was refreshed. Migration was measured in real time 
using the POLARstar Omega plate reader (BMG Labtech).  Migration speed 
was measured by calculating the area under the curve for each well and 
pictures were taken before and after the migration assays.   
Continuous real-time cell analysis (RTCA) assay 
In paper II, we additionally performed an assay to examine cell adhesion 
based on continuous measurement of electrode impedance. The presence of 
cells on electrodes’ surface affects the local ionic environment at the 
electrode/solution interface, leading to an increase in electrode impedance 
(Figure 7). The more cells attached to the electrodes, the more electrode 
impedance increases. The electrode impedance, which is displayed as Cell 
Index (CI) values, can hence be used to monitor and quantify the ability of 
cells to adhere to the electrode. 
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In this study we used the xCELLigence RTCA system (Roche Applied 
Science) to examine cell adhesion and spreading after knockdown of MYO1C 
compared to the control samples. 
Figure 6. A schematic drawing of measuring the signal in of RTCA system to gain 
information corresponding to cell adhesion. Courtesy of ACEA Biosciences.  
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Serum activation assay  
Growth factor can stimulate signaling pathways through binding to their 
respective receptors and activating the downstream signal transduction 
cascade. In paper II, we were interested to examine whether MYO1C is 
involved in activation of PI3K/AKT and ERK/RAS signaling pathways.   
To address this, we performed serum activation assay. Cells treated with 
MYO1C-targeted siRNA, hence with depleted MYO1C expression, were 
serum-starved for 24 hrs and subjected to serum stimulation. At 1, 5 and 20 
minutes post serum stimulation we examined expression of AKT and ERK 
and their activated forms using Western blot analysis. 
3.6 Statistical analysis 
The statistical analysis software SPSS (Statistical Package for the Social 
Sciences; IBM SPSS Data Collection) was used to compare two populations 
by applying two-tailed Student’s t-test in Paper I and II.  In addition, 
normalized values were arranged and plotted as bar diagram using Prism6 
(GraphPad Software) that once again tested for statistically significant 
difference in a non-pairwise fashion.  Paired analysis based on Student’s  
t-test was only employed to assess differential protein expression between 
CRC samples and its corresponding mucosa in Paper III. The data were 
presented as mean ± standard deviation (SD). A probability value (p-value) 
less than 0.05 were regarded as a level of statistical significance in all tests. 
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4 RESULTS AND DISCUSSION 
In the previous work, a minimal region of recurrent deletion/allelic loss distal 
to the Tp53 gene was identified in an experimental rat model for endometrial 
carcinoma (EC) [69].  This finding was intriguing, since similar observation 
of deletion at the homologous position on human chromosome 17, not 
associated with TP53 mutation, has been reported in several types of human 
tumors [70-73]. An important tumor suppressor gene located close to, but 
distinct of Tp53 was thus suggested. In a comparative genomic analysis, the 
candidate region was narrowed down to a segment harboring 16 known and 
three predicted genes. Using quantitative real-time PCR for all 19 genes in a 
panel of experimental ECs and control samples, Myo1c (myosin IC) and 
Inpp5k (inositol polyphosphate 5-phosphatase K) were singled out as the best 
candidates [74]. In the present PhD research work, we focused on the 
potential tumor suppressor activity of MYO1C.     
4.1 Paper I 
Several reports indicate a commonly deleted chromosomal region 
independent from, and distal to the TP53 locus in a variety of human tumors. 
In a previous study from our group, we reported a similar finding in a rat 
tumor model for endometrial carcinoma. Through developing a deletion map, 
we narrowed the candidate region to 700 kb, harboring 19 genes.  
The real-time qPCR analysis suggested Hic1 (hypermethylated in cancer 1), 
Inpp5k (inositol polyphosphate-5-phosphatase K; a.k.a. Skip, skeletal muscle 
and kidney-enriched inositol phosphatase) and Myo1c (myosin IC) as the best 
targets for the observed deletions. No mutation in coding sequences of these 
genes was detected; hence the observed low expression suggested a 
haploinsufficient mode of function for these potential tumor suppressor 
genes. Both Inpp5k and Myo1c were down regulated at mRNA and/or 
protein levels, which could be rescued in gene expression restoration assays. 
This could not be shown for Hic1. Innp5k and Myo1c were thus suggested as 
the best targets for the deletions in the candidate tumor suppressor region. 
Then, Innp5k and Myo1c were identified as the best targets for the deletions 
in the candidate tumor suppressor region. INPP5K and MYO1C are located 
adjacent to each other within the reported independent region of tumor 
suppressor activity located on chromosome arm 17p distal to TP53 in human 
tumors. There was no previous report on the tumor suppressor activity of 
MYO1C and INPP5K; however, overlapping roles in PI3K/AKT signaling, 
known to be vital for the cell growth and survival, were reported for both 
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genes. Moreover, there were reports on tumor suppressor activity of other 
members of the gene families that INPP5K and MYO1C belong. Functional 
significance of the MYO1C candidate tumor suppressor gene in cancer 
pathways was selected for further investigation in the continued research 
work. 
4.2 Paper II 
In this work, by using clinical samples along with cell-based functional 
assays, we aimed to examine the original hypothesis that MYO1C acts as a 
tumor suppressor gene in relation to a number of the Hanahan and 
Weinberg’s proposed ‘Hallmarks of Cancer’ [75, 76]. 
Our analysis showed a significant negative association between MYO1C 
protein level and the endometrial carcinoma tumor stage. Over-expression of 
MYO1C led to a significant decrease in cell proliferation and reduction of 
MYO1C protein resulted in an opposite effect. Furthermore, we found that 
reduced MYO1C expression impaired cell migration, cell spreading and cell 
adhesion. Overexpression of MYO1C protein resulted in an increase of 
p110α protein, decrease of PTEN and AKT levels as well as a decrease of 
activated AKT. Lastly, we showed that the decrease of MYO1C protein 
sensitized fast serum-induced activation of AKT.  
Taken altogether, our analysis revealed a negative correlation between high 
MYO1C level and activation of PI3K/AKT signaling as well as the ability of 
cells to proliferate. We additionally showed that lowered expression of 
MYO1C resulted in impaired cell migration and cell adhesion that could 
support of cells escaping from cell contact inhibition in favor of cancer 
development.  
4.3 Paper III 
Alterations resulting in activation of the PI3K/AKT pathway are commonly 
found in many types of human cancers, including in colorectal cancer (CRC). 
There is evidence suggesting that deregulated activation of the PI3K/AKT 
signaling pathway can function both as early and late event during CRC 
carcinogenesis. Against this background, we aimed to investigate expression 
of MYO1C, which was suggested to be involved in the PI3K/AKT signaling 
pathway, in CRC samples as well as to assess a potential correlation between 
MYO1C mRNA expression and protein level with tumor stage. 
Our analysis revealed that MYO1C was significantly down-regulated in CRC 
samples in comparison with their corresponding normal-appearing mucosa. 
However, down-regulation of MYO1C was not correlated with tumor stage, 
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suggesting that depletion of MYO1C was important for CRC development in 
general. We additionally found that levels of PTEN, ERK and pERK were 
lower in CRC in comparison with their corresponding tumor-adjacent 
normal-appearing mucosa sample, and the total RAS protein was 
significantly higher in tumor-adjacent mucosa compared to both tumor tissue 
and normal healthy mucosa. However, we could not link low levels of 
myosin IC to activation of neither the PI3K/AKT nor RAS pathways in the 
CRC samples. Accordingly, our data suggested either depletion of MYO1C 
affected these pathways in early steps of CRC tumorigenesis, which could 
not be detected in fully blown CRC samples, or MYO1C exerted its tumor 
suppressor function through a different mechanism(s).   
4.4 Paper IV 
The previous work suggested that PI3K/AKT and RAS/ERK are most likely 
not the only pathways through which MYO1C may exert its tumor suppressor 
activity. Accordingly, we designed a high-throughput genome-wide assay to 
understand new interactions of MYO1C with other gene candidates/pathways. 
We identified an early and significant response to MYO1C knockdown on 
PI3K/AKT signaling pathway of which six genes were identified as having 
expression patterns highly correlated to that observed for MYO1C. The 
analysis additionally identified several late response genes/pathways with 
known cancer-related function, providing additional supporting evidence for 
the initial hypothesis of tumor suppressor activity of MYO1C. Identification 
of PI3K/AKT signaling as an early response to MYO1C knockdown could 
explain the lack of correlation between MYO1C expression and expression of 
components of PI3K/AKT in the fully developed CRC samples, as identified 
in Paper III. 
As a purely exploratory study, the presented data have some limitations. The 
lack of replicates in the experimental design is a definite limitation, but when 
designing the study, we prioritized more time points over duplicates, to 
ensure capturing the dynamics of gene regulation and provide sufficient data 
for correlation analyses. Another limitation is the inaccuracy in measuring 
low concentration gene expressions when using microarray analysis in 
comparison with qPCR. To minimize this limitation, we chose to use the 3D-
Gene platform from Toray, which has special features, such as a black resin 
substrate which produces a lower background signal and a columnar structure 
upon which the probers are mounted giving more uniform results [77].  
 
Cellular, Molecular and Functional Characterization of the Tumor Suppressor Candidate 
MYO1C 
26 
5 CONCLUSION AND  
FUTURE PERSPECTIVE 
Discovery of a novel cancer-related gene may not only help to understand 
cancer pathogenesis, but it also gives a new hint of hope for new treatments 
leading toward the cure of cancer. Moreover, identification of new cancer 
biomarkers will serve as efficient tools for early detection, better diagnosis 
and prognosis, and improved classification of cancers. 
This PhD project is a very first step to allow a better understanding of the 
potential role(s) of a novel tumor suppressor candidate, MYO1C, in different 
cell phenotypes such as cell proliferation, adhesion, and migration together 
with investigating the interplay of this protein with various components of 
the signaling pathways involved in cancer development.  
In this study, we found the expression of MYO1C was strongly and 
significantly lowered in at least two cancer types: endometrial carcinoma and 
colorectal cancer. We additionally found that low expression of MYO1C in 
endometrial carcinoma was correlated with tumor stage; however, these 
initial findings need to be verified and confirmed in bigger panels of tumors 
as well as in other cancer types.  
Through our analyses, we could additionally produce some initial data on the 
potential tumor suppressor functions of MYO1C that can be directly related to 
at least three of the Hanahan and Weinberg’s proposed ‘Hallmarks of 
Cancer’: 
I. Sustaining proliferative signaling through negative 
correlation between MYO1C expression and ability of cells 
to proliferate 
II. Evading growth suppressors through evading cell contact 
inhibition, as depletion of MYO1C resulted in reduced 
ability of cells to adhere to the surface 
III. Resisting cell death as indicated by the data from 3D-
miroarray analysis that suggested apoptosis pathway was 
down-regulated in response to MYO1C depletion 
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Data from the 3D-miroarray experiments additionally suggested that 
depletion of MYO1C resulted in up-regulation of cell metabolism, which is 
an emerging ‘Hallmarks of Cancer’ [76] that features in the context of cancer 
development. 
Future perspective 
Evasion from growth inhibitory signals and acquiring unlimited replicating 
potential are two hallmarks of cancer that contribute to tumorigenesis in the 
favor of net cell growth. The work presented here is just the beginning of the 
whole story. The very next step for this project will be to verify data from 
high throughput 3D-microarray by performing real-time RT-PCR, and in 
doing so, it is interesting to explore the expression of genes related to 
apoptosis pathway and shelterin complex, vesicle transport, metabolism, cell 
cycle pathway, to name a few. These investigations are in process.  
Our research group is additionally planning to investigate the potential role of 
MYO1C in other cancer types, namely prostate cancer and neuroblastoma. 
Another dimension of the ongoing research is to identify protein(s) to which 
MYO1C can physically interact through performing pull-down experiment, 
using a yeast two-hybrid system. These approaches together will certainly 
produce further evidence for the functional significance of myosin IC in 
cancer. 
 
“As the ending of the thesis, I would like to repeat myself how we 
began with this PhD research project. The main aim of the project 
was to investigate the role and function of myosin IC as a potential 
tumor suppressor gene. At the end of my PhD study I could produce 
some evidences to support this original assumption as well as could 
propose a number of genes and pathways that MYO1C could possibly 
exert its tumor suppressor function by the interplay of them. 
However, there is still much work left for identification of the precise 
mechanism(s) through which MYO1C may exert its role in tumor 
development. It is also good to notify that INPP5K, the second tumor 
suppressor candidate identified in paper I, is waiting for its turn to be 
attended.”  
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“Cancer affects all of us, whether you’re a daughter, mother,  
sister, friend, coworker, doctor, or patient.”  
– Jennifer Aniston 
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